Danaher Corporation $DHR Shares Newly Acquired by KG Capital Management

KG Capital Management purchased a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,808 shares of the conglomerate’s stock, valued at approximately $622,000.

Other large investors also recently bought and sold shares of the company. EP Wealth Advisors LLC purchased a new stake in Danaher in the 2nd quarter worth $3,807,000. Puzo Michael J purchased a new position in Danaher during the second quarter valued at $8,624,000. Madison Asset Management LLC purchased a new position in Danaher during the second quarter valued at $85,451,000. First Nebraska Trust Co purchased a new position in Danaher during the second quarter valued at $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new stake in shares of Danaher in the third quarter valued at about $592,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Stock Up 0.8%

Shares of DHR opened at $224.65 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The stock has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The stock has a 50 day moving average price of $212.92 and a 200 day moving average price of $195.39.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 EPS. Equities research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research reports. UBS Group started coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price for the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Evercore reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Finally, Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.